Cargando…
γ-Secretase Modulators: Can We Combine Potency with Safety?
γ-Secretase modulation has been proposed as a potential disease modifying anti-Alzheimer's approach. γ-Secretase modulators (GSMs) cause a product shift from the longer amyloid-beta (Aβ) peptide isoforms to shorter, more soluble, and less amyloidogenic isoforms, without inhibiting APP or Notch...
Autores principales: | Gijsen, Harrie J. M., Mercken, Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534213/ https://www.ncbi.nlm.nih.gov/pubmed/23365783 http://dx.doi.org/10.1155/2012/295207 |
Ejemplares similares
-
APLP1 as a cerebrospinal fluid biomarker for γ-secretase modulator treatment
por: Sjödin, Simon, et al.
Publicado: (2015) -
Qualitative changes in human γ-secretase underlie familial Alzheimer’s disease
por: Szaruga, Maria, et al.
Publicado: (2015) -
The mechanism of γ-Secretase dysfunction in familial Alzheimer disease
por: Chávez-Gutiérrez, Lucía, et al.
Publicado: (2012) -
γ-Secretase modulators exhibit selectivity for modulation of APP cleavage but inverse γ-secretase modulators do not
por: Lessard, Christian B., et al.
Publicado: (2020) -
Extracellular interface between APP and Nicastrin regulates Aβ length and response to γ‐secretase modulators
por: Petit, Dieter, et al.
Publicado: (2019)